Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a health and wellness company specializing in the formulation of medicinal mushrooms health products and novel delivery platforms for the pharmaceutical and nutraceutical industries, today announced its entry into a definitive agreement to acquire Tassili Life Sciences Corp. Per the update, the move will expand the Company’s preclinical trial pipeline, as well as its aggregation of broad intellectual property (IP) related to the development of novel psychedelics therapeutics and their delivery systems, targeting multiple pathological psychological diseases. Tassili has partnered with a multidisciplinary team of scientists and physicians at the University of Miami to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries (“mTBI”) and/or post-traumatic stress disorder (“PTSD”). “Mild traumatic brain injury, especially concussion, is a significant cause of morbidity worldwide,” Dr. Michael Hoffer, professor of otolaryngology and neurological surgery at University of Miami’s Miller School of Medicine, stated in the news release. “What many do not realize is that TBI often occurs alongside PTSD. Up to 40% of people impacted by mTBI, a head injury causing a temporary change in mental status or consciousness, or TBI in general, also suffer from PTSD. This combination of mTBI and PTSD is even more common in U.S military members and presents a vast patient population to service and potentially heal with our novel therapeutics under development.”
To view the full press release, visit http://cnw.fm/b3JCA
About Champignon Brands Inc.
Champignon Brands Inc. (CSE: SHRM) is a research driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes for indications such as depression and Post Traumatic Stress Disorder (“PTSD”), as well as substance and alcohol use disorders. Champignon continues to be inspired by sustainability, as its medicinal mushroom infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.Champignonbrands.com.
NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.